From Hitachi Medical Systems America Inc.;
the AIRIS II, an entry in the diagnostic category of open MR systems, was designed by Hitachi Medical Systems America Inc. (Twinsburg, OH, USA) and Hitachi Medical Corp. (Tokyo) and is manufactured by the Tokyo branch. A 0.3 T field-strength magnet and phased array coils deliver high image quality without the need for a tunnel-type high-field system, thereby significantly improving patient comfort not only for claustrophobic patients.

The company changed its name from Advanced Magnetics, Inc. to AMAG Pharmaceuticals, Inc. in July 2007.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, developed and manufactured organ-specific diagnostic contrast agents that provide clearer images during magnetic resonance imaging (MRI) tests used to detect tumors and other abnormalities.
The company had two MRI related products on the market: Feridex I.V. (for the diagnosis of liver lesions) and GastroMARK (used for bowel and abdominal MR imaging). In November 2008, AMAG Pharmaceuticals, Inc. decided to discontinue the manufacturing of Feridex. The development of Combidex as a contrast agent for lymph disease has also been stopped.
The Company has now two commercial products: Feraheme® and GastroMARK®. Feraheme® is the trade name of Ferumoxytol (formerly Code 7228) and is indicated for the treatment of iron deficiency anemia. Feraheme® is also being developed as a diagnostic agent for vascular-enhanced magnetic resonance imaging (MRI) to assess peripheral arterial disease.

MRI Contrast Agents:

Founded in 1991, ImaRx Pharmaceutical Corp. designs, develops and markets pharmaceuticals for medical imaging (MRI, ultrasound and computed tomography) for the radiological imaging industry.
ImaRx Pharmaceutical Corp., announced 1999 that it has been acquired by E.I DuPont de Nemours and Co., Inc.. The terms of the acquisition provide a royalty-free licensing arrangement with a newly-formed company, ImaRx LLC ("LLC"), to pursue and develop new products and technologies for drug and gene delivery independent from DuPont. Yamanouchi Pharmaceutical Co. Ltd., ImaRx' licensee for Asian territories for this product, will continue to develop the product in Asia as DuPont's licensee. ImaRx LLC will have ownership of all other targeted and therapeutic products previously owned by ImaRx, including imaging products outside of diagnostic ultrasound imaging and two other imaging products, SonoRx® and LumenHance®, which are both FDA approved and licensed to BRACCO Diagnostics.

MRI Contrast Agents:

From Siemens Medical Systems; Received FDA clearance in 2010.
MAGNETOM Skyra is a top-of-the-line, patient friendly wide bore 3 Tesla MRI system.
The system is equipped with the Tim 4G and Dot system (Total imaging matrix and Day optimizing throughput), to enhance both productivity and image quality with the complete range of advanced applications for clinical routine and research. Tim 4G features lighter, trimmer MRI coils that take up less space inside the magnet but deliver a high coil element density with increased signal to noise ratio and the possibility to use high iPAT factors.

From Toshiba America Medical Systems Inc.;
With its high-field strength, the Vantageâ„¢ delivers the clinical capabilities and image quality expected by cardiologists, while simultaneously offering patients a more comfortable and non-invasive option, said Dane Peshe, director, MRI Business Unit, Toshiba America Medical Systems. Vantageâ„¢ supports a full complement of cardiovascular imaging studies, ranging from stroke evaluation to peripheral vascular imaging. Additionally, the ultra short bore design offers patients a greater feeling of openness that reduces claustrophobic sensations, while Toshiba's exclusive, patented Pianissimoâ„¢ technology reduces scan noise by as much as 90 percent for a more pleasant experience.'